Levodopa Response Determinants in PSP — Biomarker-Guided Prediction Study

Hypothesis

Primary Hypothesis: PSP patients with preserved nigrostriatal dopamine terminal integrity (as measured by DaTscan and CSF biomarkers) will demonstrate significantly better levodopa response, and this can be predicted by a biomarker panel measured at baseline.

Secondary Hypothesis: Genetic variants in dopamine metabolism (COMT, DBH, DRD2) and levodopa transport (SLC22A1) modify levodopa response in PSP, explaining inter-individual variability.

Open Question Source

Hypothesis

Primary Hypothesis: PSP patients with preserved nigrostriatal dopamine terminal integrity (as measured by DaTscan and CSF biomarkers) will demonstrate significantly better levodopa response, and this can be predicted by a biomarker panel measured at baseline.

Secondary Hypothesis: Genetic variants in dopamine metabolism (COMT, DBH, DRD2) and levodopa transport (SLC22A1) modify levodopa response in PSP, explaining inter-individual variability.

Open Question Source

This experiment addresses the CBS/PSP Cure Roadmap knowledge gap: "Why do only 30-40% of PSP patients respond to levodopa?"

Validation Protocol

Study Design

• Type: Prospective, multi-center, biomarker-guided clinical study
• Cohort:
• PSP diagnosis (MDS-2017 criteria)
• Treatment-naive or levodopa washout ≥4 weeks
• Able to undergo MRI, PET, CSF collection
• Sample Size: N=200 (80% power for effect size d=0.4)

Study Arms

| Arm | Description | N |
|-----|-------------|---|
| Derivation | Biomarker discovery | 100 |
| Validation | Independent validation | 100 |

Clinical Assessment

• Single dose 200/50 (Sinemet)
• Pre/post UPDRS-III at 0, 1, 2, 3 hours
• Responder definition: ≥30% improvement

• Titration to max tolerated (up to 2000mg/d)
• Response at 3 months
• Clinical global impression

Biomarker Panel

| Category | Markers | Platform |
|----------|---------|----------|
| Dopaminergic integrity | DaTscan (binding ratio), CSF homovanillic acid | SPECT, LC-MS |
| Neurodegeneration | CSF NfL, p-tau181, total tau | Simoa |
| Neuroinflammation | CSF IL-6, TNF-α, YKL-40 | ELISA |
| Genetic | PGx panel (COMT, DBH, SLC22A1, DRD2) | TaqMan array |

Imaging

• MRI: Volumetric, neuromelanin-sensitive, DTI
• PET: 18F-FP-DTBZ (VMAT2), tau PET (PI-2620)
• DaTscan: SPECT binding in caudate/putamen

Model System

Human Clinical Study

• Sites: 5-8 academic movement disorder centers
• Duration: 3 months per patient
• Ethical: IRB-approved, informed consent

Validation Models

• Post-mortem brain: Correlate biomarker profiles with dopaminergic neuron counts
• Patient-derived cells: iPSC dopaminergic neurons for pharmacogenomics

Expected Outcomes

Primary

Secondary

Effect Size Expectations

• Biomarker AUC: 0.78-0.85 for optimal panel
• Response rate improvement: From 35% to 65% with biomarker selection

Feasibility Estimate

Technical: 9/10

• All assays are clinically validated and available
• DaTscan and levodopa challenge are standard-of-care
• Multi-center networks exist (e.g., CurePSP centers)

Timeline: 8/10

• Year 1: Site setup, enrollment begin (6 months)
• Year 2: Enrollment complete, initial analysis (12 months)
• Year 3: Validation cohort, publication (12 months)

Overall: 8.5/10

Cost Estimate

| Item | Cost (USD) |
|------|------------|
| Clinical operations (200 pts, 8 sites) | $800,000 |
| PET imaging (DaTscan, VMAT2) | $400,000 |
| Tau PET | $200,000 |
| CSF biomarker assays | $200,000 |
| Genetic analysis | $80,000 |
| MRI | $120,000 |
| Data management | $100,000 |
| Personnel (study coordinator × 3 years) | $300,000 |
| Total | $2,200,000 |

Risk Assessment

| Risk | Likelihood | Impact | Mitigation |
|------|-----------|--------|-----------|
| Enrollment challenges | Medium | High | Multiple sites, broad criteria |
| Biomarker assay variability | Low | Medium | Central lab processing |
| Lost to follow-up | Medium | Medium | Retention strategies |

Scientific Value

Score: 8/10 — Addresses an important clinical question but mechanism is already partially understood (dopamine terminal loss).

Disease Impact

Score: 9/10 — Would immediately improve clinical care by predicting levodopa responders and avoiding ineffective treatment in non-responders.

References

Related Pages

• [CBS/PSP Cure Roadmap](/mechanisms/cbs-psp-cure-roadmap)
• [Personalized Treatment Plan — CBS/PSP](/therapeutics/personalized-treatment-plan-atypical-parkinsonism)
• [Experiment Priority Index](/experiments/experiment-priority-index)